Figure 5. Activities of MW1219 on insulin and GLP-1 secretion in db/db mice.

Following 6 weeks of oral treatment with MW1219, (A) insulin and (B) GLP-1 levels after an oral glucose bonus were determined. *P<0.05, **P<0.01 vs. vehicle group, and ^#P<0.05 vs. sitagliptin group (1 mg/kg) as determined with One-Way ANOVA test.